logo
Nearly 30,000 pounds of Chomps Beef Sticks recalled over potential metal in meat

Nearly 30,000 pounds of Chomps Beef Sticks recalled over potential metal in meat

Yahoo22-03-2025

Chomps' manufacturer recalled nearly 30,000 ready-to-eat beef sticks after customers reported metal in the product.
Idaho Smokehouse Partners notified the U.S. Department of Agriculture's Food Safety and Inspection Service that they received two complaints from customers reporting pieces of metal in their Chomps sticks.
The Idaho-based manufacturer then issued a voluntary recall Thursday for approximately 29,541 pounds of ready-to-eat beef stick products, shipped to stores in California and Illinois, saying they may have been contaminated with metal.
Chomps made the decision to "voluntarily" expand the recall to include Chomps Original Turkey sticks to ensure that any possible product packaged during that timeframe was removed.
There have been no confirmed reports of injuries due to the consumption of the contaminated beef sticks.
'Prioritizing the safety and trust of our customers is at the heart of everything we do," Chomps said in a Saturday statement. "Out of an abundance of caution, Chomps made the decision to include additional product beyond what was required to ensure all potentially affected items were removed from the market. "
Here's what to know about the Chomps recall and how to remedy the situation.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
The potentially contaminated ready-to-eat beef and turkey sticks were packaged at a single facility between January 16 and January 23, 2025, according to the Chomps recall website. The beef sticks have a Feb. 10, 2026 expiration date.
"FSIS is concerned that some product may be in consumers' pantries," the agency said. "Consumers who have purchased these products are urged not to consume them. These products should be thrown away or returned to the place of purchase."
Anyone concerned about a potential injury related to the recall should contact a health care professional immediately.
Chomps customers utilize a search function available on the Chomps website to see if their products were impacted by the recall or can check if the relevant lot code, listed below, can be found on the Chomps stick.
Chomps Original Beef Stick product information:
Product: 1.15-ounce vacuum-sealed packages of "Chomps Original Beef Stick Mild"
Expiration date: 2/10/2026
Lot codes: 6220A 25016, 6220A 25017, 6220A 25018, 6220A 25020, 6220A 25021 and 6220A 25022
Establishment number: 6220A
Chomps Original Turkey Stick product information:
Product: 1.15-ounce vacuum-sealed packages of "Chomps Original Turkey Stick"
Lot codes: P6220A 25022 and P6220A 25023
Consumers with questions about the current recall may contact Idaho Smokehouse Partners by phone at 208-227-5282.
This story was updated to include new information and correct an error.
This article originally appeared on USA TODAY: Chomps Beef Sticks recall: Nearly 30,000 pounds affected

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth Group received multiple bids for Latin American operations
UnitedHealth Group received multiple bids for Latin American operations

Yahoo

time34 minutes ago

  • Yahoo

UnitedHealth Group received multiple bids for Latin American operations

-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

Yahoo

time39 minutes ago

  • Yahoo

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@

UMMC expands health care access with UMMC Madison
UMMC expands health care access with UMMC Madison

Yahoo

timean hour ago

  • Yahoo

UMMC expands health care access with UMMC Madison

CANTON, Miss. (WJTV) – The University of Mississippi Medical Center (UMMC) acquired Merit Health Madison, which now operates as UMMC Madison. With 67 licensed beds, officials said the Canton-based hospital will expand UMMC's mission to deliver high-quality, accessible care to more Mississippians while providing additional training opportunities for future health care providers. Lyme-disease isn't the only tick-borne threat. Doctors warn these other diseases are spreading 'As Mississippi's only academic medical center, we must continue to be focused on our three-part mission to educate the next generation of health care providers, conduct impactful research and deliver accessible high-quality health care,' said Dr. LouAnn Woodward, vice chancellor of health affairs. 'Every decision we make is rooted in our mission.' The acquisition was finalized May 1. As the full owner, UMMC will integrate the facility more closely into its academic and health care system. UMMC Madison will continue to provide a wide range of community hospital services, including emergency services, medical-surgical care, ICU, pulmonology, pathology, cardiology, radiology, neurology, nephrology, general surgery and GI services. The hospital will operate as a community hospital. UMMC Madison will also become a training site for medical students, residents and fellows, who will have the opportunity to learn at a community hospital. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store